Insulet (PODD) Stock Forecast & Price Target

Insulet is fundamentally attractive because it leads the insulin patch pump category with the differentiated Omnipod platform, whose wearable, tubeless design, integrated CGM compatibility, and automated insulin delivery capabilities reduce barriers to access and improve the patient experience, supporting durable adoption across its installed base of more than 600,000 users worldwide. The company also has meaningful growth levers in front of it, including expansion in type 2 insulin-intensive diabetes, international penetration, and product/algorithm enhancements, with management pointing to Omnipod Discover’s early traction among over 12,000 patients and more than 1,600 health care professionals, while BTIG models 2026 revenue of about $3.289 billion and adjusted EPS of $6.49 alongside 31% year-over-year adjusted EPS growth and 90 bps of adjusted EBIT margin expansion. Although near-term retention issues in the U.S. type 2 population and incoming competition create execution risk, the excerpted analysis suggests these are fixable operational challenges rather than structural flaws, and a successful improvement in retention, utilization, and margin expansion would reinforce the company’s scale advantages and long-term profitability profile.

Insulet is facing a negative fundamental setup because US Omnipod growth is decelerating, with the company lowering its full-year revenue outlook after 2Q despite a revenue beat, while management’s own commentary points to weaker Type 2 utilization and retention that are expected to persist through the remainder of the year. The outlook is further pressured by rising competitive and adoption risk as newer tubeless entrants are expected to intensify share loss concerns in 4Q26-mid 2027 and beyond, making it harder for investors to underwrite sustained multiple expansion until the company proves it can coexist with those competitors. In addition, management credibility has been dented by mixed guidance, a softer stance on the long-term plan, and 2 recalls/field actions, even though the business still targets more than 30% adjusted EPS growth and over $1 billion of R&D spending over the next three years, leaving estimates vulnerable and the valuation at risk of staying disconnected from the growth profile for an extended period.